HAYA Therapeutics
HAYA Therapeutics is a biotechnology company developing precision RNA-guided regulatory genome targeting therapeutics for rare, common, chronic, and age-associated diseases. Their platform focuses on long non-coding RNAs (lncRNAs) to reprogram pathological cell states for diseases like cardiovascular, metabolic, and cancer. HAYA's lead therapeutic candidate is HTX-001, in development for the treatment of heart failure.
Funding Round: Non-dilutive funding
Funding Amount: $1.64M
Date: 12-Feb-2025
Investors: Innosuisse
Markets: Biotech, Oncology, Therapeutics
HQ: Lausanne, Switzerland
Founded: 2017
Website: https://www.hayatx.com/
LinkedIn: https://www.linkedin.com/company/haya-therapeutics/
Twitter: https://x.com/HAYA_lncRNA
Crunchbase: https://www.crunchbase.com/organization/haya-therapeutics
Leave a Comment
Comments
No comments yet.